The Wnts of change: How Wnts regulate phenotype switching in melanoma

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1856, Issue 2, 2015, Pages 244-251

  Webster, Marie R ^a   Kugel, Curtis H ^a   Weeraratna, Ashani T ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Immune microenvironment; Melanoma; Phenotype switching; Therapy resistance; Wnt signaling

Indexed keywords

BETA CATENIN; CALCIUM ION; FRIZZLED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PROTEIN KINASE C; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; WNT PROTEIN; TUMOR PROTEIN;

CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELL FATE; DOWN REGULATION; HUMAN; IMMUNE EVASION; IMMUNOREGULATION; IMMUNOSURVEILLANCE; MELANOMA; METASTASIS; NONHUMAN; PHENOTYPE; PHENOTYPE SWITCHING; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; BIOLOGICAL MODEL; CELL DIFFERENTIATION; CELL PLASTICITY; CELL PROLIFERATION; METABOLISM; PATHOLOGY; TUMOR INVASION;

ANIMALS; CELL DIFFERENTIATION; CELL PLASTICITY; CELL PROLIFERATION; HUMANS; MELANOMA; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PHENOTYPE; TUMOR MICROENVIRONMENT; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84946706255     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2015.10.002     Document Type: Review

References (107)

1. O'Connell M.P., et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 2013, 3(12):1378-1393.
2. Biddle A., et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res. 2011, 71(15):5317-5326.
3. Dang H., Ding W., Emerson D., Rountree C.B. Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics. BMC Cancer 2011, 11(1):396.
4. Dissanayake S.K., et al. Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res. 2008, 68(24):10205-10214.
5. Witze E.S., Litman E.S., Argast G.M., Moon R.T., Ahn N.G. Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors. Science 2008, 320(5874):365-369.
6. Mani S., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
7. Morel A., et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3.
8. Hoek K.S., et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 2008, 68(3):650-656.
9. Dissanayake S.K., et al. Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res. 2008, 68(24):10205-10214.
10. Dissanayake S.K., et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J. Biol. Chem. 2007, 282(23):17259-17271.
11. Curley D.P., Bosenberg M.W. A new mechanism of release from senescence: suppression of p16INK4a by beta-catenin. Pigment Cell Melanoma Res. 2008, 21(1):5-6.
12. Delmas V., et al. Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev. 2007, 21(22):2923-2935.
13. Bachmann I.M., Straume O., Puntervoll H.E., Kalvenes M.B., Akslen L.A. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin. Cancer Res. 2005, 11(24 Pt 1):8606-8614.
14. Biechele T.L., et al. Chemical-genetic screen identifies riluzole as an enhancer of Wnt/beta-catenin signaling in melanoma. Chem. Biol. 2010, 17(11):1177-1182.
15. Biechele T.L., Chien A.J. Re: specific targeting of Wnt/beta-catenin signaling in human melanoma cells by a dietary triterpene lupeol. Carcinogenesis 2011, 32(1):120. author reply 121.
16. Chien A.J., et al. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(4):1193-1198.
17. Demunter A., Libbrecht L., Degreef H., De Wolf-Peeters C., van den Oord J.J. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations. Mod. Pathol. 2002, 15(4):454-461.
18. Nemeth M.J., Topol L., Anderson S.M., Yang Y., Bodine D.M. Wnt5a inhibits canonical Wnt signaling in hematopoietic stem cells and enhances repopulation. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(39):15436-15441.
19. Topol L., et al. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J. Cell Biol. 2003, 162(5):899-908.
20. O'Connell M.P., Weeraratna A.T. Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt. Pigment Cell Melanoma Res. 2009.
21. Cheng M., et al. The p21Cip1 and p27Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 1999, 18(6):1571-1583.
22. Goodall J., et al. Brn-2 expression controls melanoma proliferation and is directly regulated by β-catenin. Mol. Cell. Biol. 2004, 24(7):2915-2922.
23. Ghosh M.C., et al. Activation of Wnt5A signaling is required for CXC chemokine ligand 12-mediated T-cell migration. Blood 2009, 114(7):1366-1373.
24. Bergenfelz C., et al. Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients. J. Immunol. 2012, 188(11):5448-5458.
25. Pereira C., Schaer D.J., Bachli E.B., Kurrer M.O., Schoedon G. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler. Thromb. Vasc. Biol. 2008, 28(3):504-510.
26. Ramirez A.G., Wages N.A., Hu Y., Smolkin M.E., Slingluff C.L. Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials' experience. Cancer Immunol. Immunother.:CII 2015.
27. Nusse R., Varmus H.E. Wnt genes. Cell 1992, 69(7):1073-1087.
28. Miller J. The Wnts. Genome Biol. 2001, 3(1). reviews3001.3001 - reviews3001.3015.
29. Slusarski D.C., Corces V.G., Moon R.T. Interaction of Wnt and a frizzled homologue triggers G-protein-linked phosphatidylinositol signalling. Nature 1997, 390(6658):410-413.
30. Liu X., et al. Activation of a frizzled-2/beta-adrenergic receptor chimera promotes Wnt signaling and differentiation of mouse F9 teratocarcinoma cells via Galphao and Galphat2. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:14383-14388.
31. Malbon C.C., Wang H.-y., Moon R.T. Wnt signaling and heterotrimeric G-proteins: strange bedfellows or a classic romance?. Biochem. Biophys. Res. Commun. 2001, 287(3):589-593.
32. Li Y., Bu G. LRP5/6 in Wnt signaling and tumorigenesis. Future Oncol. 2005, 1(5):673-681.
33. Masiakowski P., Yancopoulos G.D. The Wnt receptor CRD domain is also found in MuSK and related orphan receptor tyrosine kinases. Curr. Biol. 1998, 8(12).
34. Rehn M., Pihlajaniemi T., Hofmann K., Bucher P. The frizzled motif: in how many different protein families does it occur?. Trends Biochem. Sci. 1998, 23(11):415-417.
35. Katoh M.K.M. Comparative genomics on ROR1 and ROR2 orthologs. Oncol. Rep. 2005, 14(5):1381-1384.
36. Masiakowski P., Carroll R.D. A novel family of cell surface receptors with tyrosine kinase-like domain. J. Biol. Chem. 1992, 267(36):26181-26190.
37. Delmas V., et al. β-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev. 2007, 21(22):2923-2935.
38. Damsky W.E., et al. Beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 2011, 20(6):741-754.
39. Mikels A.J., Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006, 4(4).
40. Wellbrock C., Arozarena I. Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. Pigment Cell Melanoma Res. 2015, 28(4):390-406.
41. Widlund H.R., et al. β-catenin-induced melanoma growth requires the downstream target microphthalmia-associated transcription factor. J. Cell Biol. 2002, 158(6):1079-1087.
42. Novak A.D.S. Signaling through beta-catenin and lef/Tcf. Cell. Mol. Life Sci. 1999, 56:523-537.
43. Carreira S., et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 2005, 433(7027):764-769.
44. Loercher A.E., Tank E.M.H., Delston R.B., Harbour J.W. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J. Cell Biol. 2005, 168(1):35-40.
45. Damsky William E., et al. β-catenin signaling controls metastasis in braf-activated pten-deficient melanomas. Cancer Cell 2011, 20(6):741-754.
46. Damsky W.E., Theodosakis N., Bosenberg M. Melanoma metastasis: new concepts and evolving paradigms. Oncogene 2014, 33(19):2413-2422.
47. Park J.-W., Jang M.-A., Lee Y.H., Passaniti A., Kwon T.K. p53-independent elevation of p21 expression by PMA results from PKC-mediated mRNA stabilization. Biochem. Biophys. Res. Commun. 2001, 280(1):244-248.
48. Yaguchi T., et al. Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells. J. Immunol. 2012, 189(5):2110-2117.
49. Topol L., et al. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent β-catenin degradation. J. Cell Biol. 2003, 162(5):899-908.
50. Sato A., Yamamoto H., Sakane H., Koyama H., Kikuchi A. Wnt5a regulates distinct signalling pathways by binding to Frizzled2. EMBO J. 2010, 29(1):41-54.
51. Da Forno P.D., et al. WNT5A expression increases during melanoma progression and correlates with outcome. Clin. Cancer Res. 2008, 14(18):5825-5832.
52. Bittner M., et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000, 406(6795):536-540.
53. Cano A., et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2000, 2:76-83.
54. Dissanayake S.K. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J. Biol. Chem. 2007, 282:17259-17271.
55. Hao L., Ha J.R., Kuzel P., Garcia E., Persad S. Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through twist and snail. Br. J. Dermatol. 2012, 166(6):1184-1197.
56. Lee J.-H., et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J. Natl. Cancer Inst. 1996, 88(23):1731-1737.
57. Shoag J., et al. PGC-1 coactivators regulate MITF and the tanning response. Mol. Cell 2013, 49(1):145-157.
58. Wittgen H.G.M., van Kempen L.C.L.T. Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res. 2007, 17(6):400-409.
59. St-Pierre J., et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006, 127(2):397-408.
60. Vazquez F., et al. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 2013, 23(3):287-301.
61. Liu F., Fu Y., Meyskens F.L. MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE-1/Ref-1. J. Investig. Dermatol. 2008, 129(2):422-431.
62. Ziech D., Franco R., Pappa A., Panayiotidis M.I. Reactive oxygen species (ROS)-induced genetic and epigenetic alterations in human carcinogenesis. Mutat. Res. Fundam. Mol. Mech. Mutagen. 2011, 711(1-2):167-173.
63. De Donatis G.M., et al. NF-kB2 Induces Senescence Bypass in Melanoma Via a Direct Transcriptional Activation of EZH2 2015, Oncogene.
64. Patino W.D.S.J. Epigenetics of cutaneous melanoma. Adv. Dermatol. 2008, 24:59-70.
65. Venza M., et al. Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma. Biochim. Biophys. Acta (BBA) - Gene Regul. Mech. 2015, 1849(3):247-256.
66. Lauss M., et al. Genome-wide DNA methylation analysis in melanoma reveals the importance of CpG methylation in MITF regulation. J. Investig. Dermatol. 2015, 135(7):1820-1828.
67. Kostaki M., et al. High-frequency p16INK4A promoter methylation is associated with histone methyltransferase SETDB1 expression in sporadic cutaneous melanoma. Exp. Dermatol. 2014, 23(5):332-338.
68. Khuu C.H., Barrozo R.M., Hai T., Weinstein S.L. Activating transcription factor 3 (ATF3) represses the expression of CCL4 in murine macrophages. Mol. Immunol. 2007, 44(7):1598-1605.
69. Katoh M.K.M. Transcriptional mechanisms of WNT5A based on NF-κB, Hedgehog, TGFβ, and notch signaling cascades. Int. J. Mol. Med. 2009, 23:763-769.
70. Konieczkowski D.J., et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014, 4(7):816-827.
71. Bystry R.S., Aluvihare V., Welch K.A., Kallikourdis M., Betz A.G. B cells and professional APCs recruit regulatory T cells via CCL4. Nat. Immunol. 2001, 2(12):1126-1132.
72. Tap W.D., et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 2010, 12(8):637-649. (New York, N.Y.).
73. Zipser M.C., et al. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. Pigment Cell Melanoma Res. 2011, 24(2):326-333.
74. Larkin J., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015, 373(1):23-34.
75. Byers L.A., et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 2013, 19(1):279-290.
76. Liu J., et al. Targeting Wnt-driven cancer through the inhibition of porcupine by LGK974. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(50):20224-20229.
77. Biechele T.L., et al. Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci. Signal. 2012, 5(206). ra3-ra3.
78. Haq R., et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell 2013, 23(3):302-315.
79. Klarmann G., et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin. Exp. Metastasis 2009, 26(5):433-446.
80. Sabbah M., et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist. Updat. 2008, 11(4-5):123-151.
81. Roesch A., et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141(4):583-594.
82. Roesch A., et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B high cells. Cancer Cell 2013, 23(6):811-825.
83. Robert C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364(26):2517-2526.
84. Adams P.D. Remodeling of chromatin structure in senescent cells and its potential impact on tumor suppression and aging. Gene 2007, 397(1-2):84-93.
85. Wang F., et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. 1999, 5(10):2756-2765.
86. Murisier FF Genetics of pigment cells: lessons from the tyrosinase gene family. Histol. Histopathol. 21(5):567-578.
87. Gartsbein M., et al. The role of protein kinase C δ activation and STAT3 Ser727 phosphorylation in insulin-induced keratinocyte proliferation. J. Cell Sci. 2006, 119(3):470-481.
88. Sheldahl L.C., Park M., Malbon C.C., Moon R.T. Protein kinase C is differentially stimulated by Wnt and frizzled homologs in aG-protein-dependent manner. Curr. Biol. 1999, 9(13):695.
89. Aird K.M., Zhang R. Detection of senescence-associated heterochromatin foci (SAHF). Methods Mol. Biol. 2013, 965:185-196.
90. Niculescu A.B., et al. Effects of p21Cip1/Waf1 at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell. Biol. 1998, 18(1):629-643.
91. Holtzhausen A., et al. Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: opportunities for pharmacologic enhancement of immunotherapy. Cancer immuno. Res 2015, 3(9):1082-1095.
92. Mellor A.L., Munn D.H. Ido expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 2004, 4(10):762-774.
93. Mikels A.J., Nusse R. Purified Wnt5a protein activates or inhibits β-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006, 4(4).
94. waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene 1998, 16(4):431-441.
95. Ye X., et al. Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol. Cell 2007, 27(2):183-196.
96. Geyer F.C., et al. [Beta]-catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod. Pathol. 2011, 24(2):209-231.
97. Fearnhead N.S., Britton M.P., Bodmer W.F. The ABC of APC. Hum. Mol. Genet. 2001, 10(7):721-733.
98. Morin P.J., et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997, 275(5307):1787-1790.
99. Palacios J., Gamallo C. Mutations in the β-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res. 1998, 58(7):1344-1347.
100. Conde-Perez A., et al. A caveolin-dependent and PI3K/AKT-independent role of PTEN in [beta]-catenin transcriptional activity. Nat. Commun. 2015, 6.
101. Grossmann A.H., et al. The small GTPase ARF6 stimulates β-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis. Sci. Signal. 2013, 6(265). ra14-ra14.
102. Rubinfeld B., et al. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 1997, 275(5307):1790-1792.
103. Pollock P.M.H.N. Mutations in exon 3 of the beta-catenin gene are rare in melanoma cell lines. Melanoma Res. 2002, 12(2):183-186.
104. Salti G.I., et al. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res. 2000, 60(18):5012-5016.
105. Selzer E., et al. The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res. 2002, 62(7):2098-2103.
106. Hofbauer G.F.K.J., Geertsen R., Boni R., Dummer R. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res. 1998, 8(4):337-343.
107. E-h J., et al. Wnt/β-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol. Cell. Biol. 2002, 22(4):1172-1183.